PDS Biotech to Acquire Versant Pharmaceuticals
Ticker: PDSB · Form: 8-K · Filed: Mar 27, 2024 · CIK: 1472091
| Field | Detail |
|---|---|
| Company | Pds Biotechnology Corp (PDSB) |
| Form Type | 8-K |
| Filed Date | Mar 27, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00033 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, pipeline-expansion
TL;DR
PDS Biotech buying Versant Pharma to boost pipeline, deal expected Q2 2024.
AI Summary
PDS Biotechnology Corporation announced on March 27, 2024, that it has entered into a definitive agreement to acquire Versant Pharmaceuticals, Inc. The acquisition is expected to close in the second quarter of 2024, subject to customary closing conditions. This move aims to expand PDS Biotech's pipeline and therapeutic capabilities.
Why It Matters
This acquisition could significantly expand PDS Biotech's drug development pipeline and enhance its position in the biotechnology sector.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, potential overpayment, and the possibility that the acquired assets may not perform as expected.
Key Players & Entities
- PDS Biotechnology Corporation (company) — Registrant
- Versant Pharmaceuticals, Inc. (company) — Acquired company
- Delaware (jurisdiction) — State of incorporation
- 20240327 (date) — Report date
- Q2 2024 (date) — Expected closing quarter
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is to report the definitive agreement for PDS Biotechnology Corporation to acquire Versant Pharmaceuticals, Inc.
When is the acquisition of Versant Pharmaceuticals expected to close?
The acquisition is expected to close in the second quarter of 2024.
What are the conditions for the closing of the acquisition?
The closing is subject to customary closing conditions.
What is the former name of PDS Biotechnology Corporation?
The former name of PDS Biotechnology Corporation was Edge Therapeutics, Inc., with a date of name change on 20090911.
What is the principal executive office address for PDS Biotechnology Corporation?
The principal executive office address is 303A College Road East, Princeton, NJ 08540.
Filing Stats: 591 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-03-27 07:30:25
Key Financial Figures
- $0.00033 — ich registered Common Stock, par value $0.00033 per share PDSB The Nasdaq Stock Mar
Filing Documents
- ef20025224_8k.htm (8-K) — 30KB
- ef20025224_ex99-1.htm (EX-99.1) — 87KB
- ef20025224_ex99-2.htm (EX-99.2) — 34KB
- ef20025224_ex99-2slide1.jpg (GRAPHIC) — 130KB
- ef20025224_ex99-2slide2.jpg (GRAPHIC) — 390KB
- ef20025224_ex99-2slide3.jpg (GRAPHIC) — 150KB
- ef20025224_ex99-2slide4.jpg (GRAPHIC) — 140KB
- ef20025224_ex99-2slide5.jpg (GRAPHIC) — 156KB
- ef20025224_ex99-2slide6.jpg (GRAPHIC) — 146KB
- ef20025224_ex99-2slide7.jpg (GRAPHIC) — 137KB
- ef20025224_ex99-2slide8.jpg (GRAPHIC) — 132KB
- ef20025224_ex99-2slide9.jpg (GRAPHIC) — 145KB
- ef20025224_ex99-2slide10.jpg (GRAPHIC) — 153KB
- ef20025224_ex99-2slide11.jpg (GRAPHIC) — 134KB
- ef20025224_ex99-2slide12.jpg (GRAPHIC) — 134KB
- ef20025224_ex99-2slide13.jpg (GRAPHIC) — 149KB
- ef20025224_ex99-2slide14.jpg (GRAPHIC) — 127KB
- ef20025224_ex99-2slide15.jpg (GRAPHIC) — 165KB
- ef20025224_ex99-2slide16.jpg (GRAPHIC) — 186KB
- ef20025224_ex99-2slide17.jpg (GRAPHIC) — 89KB
- image00001.jpg (GRAPHIC) — 241KB
- 0001140361-24-015456.txt ( ) — 4306KB
- pdsb-20240327.xsd (EX-101.SCH) — 4KB
- pdsb-20240327_lab.xml (EX-101.LAB) — 21KB
- pdsb-20240327_pre.xml (EX-101.PRE) — 16KB
- ef20025224_8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated March 27, 2024. 99.2 Corporate Presentation (March 2024). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PDS BIOTECHNOLOGY CORPORATION Date: March 27, 2024 By: /s/ Frank Bedu-Addo, Ph.D. Name: Frank Bedu-Addo, Ph.D. Title: President and Chief Executive Officer